Molecular profile of driver genes in lung adenocarcinomas of Brazilian patients who have never smoked: implications for targeted therapies.

Rodrigo de Oliveira CavagnaFlávia Escremim de PaulaGustavo Noriz BerardinelliMurilo BonatelliIara SantanaEduardo Caetano Albino da SilvaGustavo Ramos TeixeiraBeatriz Garbe ZanioloJosiane M DiasFlávio Augusto Ferreira da SilvaCarlos Eduardo Baston SilvaMarcela Gondim Borges GuimarãesCamila Pinto BaroneAlexandre Arthur JacintoRachid Eduardo Noleto da Nóbrega OliveiraJosé Elias MiziaraPedro De Marchi Miguel Ángel Molina-Vila Letícia Ferro Leal Rui Manuel Vieira Reis

Published in: The oncologist (2024)

Brazilian LCINS exhibited a similar molecular profile to other populations, except the increased ALK and TP53 alterations. Importantly, 73% of these patients have actionable alterations that are suitable for targeted treatments.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
peritoneal dialysis
gene expression
patient reported outcomes
dna methylation
genome wide
drug delivery
transcription factor
cancer therapy
patient reported